Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 3/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.48 |
| ▸ | OGG1 | O15527 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | BACE1 | P56817 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | MPO | P05164 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16027768 | 0.78 | P2RX7 (0.59) | P2RX7KDM4EALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL31589536 | 0.78 | P2RX7 (0.59) | P2RX7KDM4EALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL658490 | 0.78 | CREBBP (0.41) | P2RX7KDM4EALDH1A1BACE1MEN1 | |
| SCHEMBL31538477 | 0.78 | P2RX7 (0.59) | P2RX7KDM4EALDH1A1SMN1; SMN2GAA | |
| SCHEMBL17697619 | 0.78 | SMN1; SMN2 (0.43) | KDM4EALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL15228258 | 0.76 | KDM4E (0.42) | KDM4EALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL3955429 | 0.75 | P2RX7 (0.55) | P2RX7KDM4EOGG1ALDH1A1LMNA | |
| SCHEMBL1855352 | 0.75 | KDM4E (0.40) | KDM4EALDH1A1BACE1SMN1; SMN2KMT2A | |
| SCHEMBL110389 | 0.75 | P2RX7 (1.00) | P2RX7KDM4EALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL2538917 | 0.74 | NPC1 (0.41) | KDM4EALDH1A1LMNASMN1; SMN2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12577228-B2 | Dihydrocyclopenta-isoquinoline-sulfonamide derivatives compounds | UCB Biopharma SRL (BE) | 2026-03-17 | — | — | US | disclosed |
| EP-4081296-B1 | DIHYDROCYCLOPENTA-ISOQUINOLINE-SULFONAMIDE DERIVATIVES COMPOUNDS | UCB Biopharma SRL (BE) | 2026-02-11 | — | — | EP | disclosed |
| US-12325678-B2 | Anti-fungals compounds targeting the synthesis of fungal sphingolipids | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2025-06-10 | — | — | US | disclosed |
| WO-2025110780-A1 | NOVEL HETEROCYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AS DNA POLYMERASE THETA INHIBITORS FOR THE PREVENTION OR TREATMENT OF CANCER | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2025-05-30 | — | — | WO | disclosed |
| CN-120040437-A | Novel heterocyclic compound and pharmaceutical composition comprising same | 株式会社大熊制药 | 2025-05-27 | — | — | CN | disclosed |
| US-20240124392-A1 | ANTI-FUNGALS COMPOUNDS TARGETING THE SYNTHESIS OF FUNGAL SPHINGOLIPIDS | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2024-04-18 | — | — | US | disclosed |
| US-11858880-B2 | Anti-fungals compounds targeting the synthesis of fungal sphingolipids | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2024-01-02 | — | — | US | disclosed |
| US-20230303517-A1 | DIHYDROCYCLOPENTA-ISOQUINOLINE-SULFONAMIDE DERIVATIVES COMPOUNDS | UCB BIOPHARMA SRL (SOCIETE A RESPONSABILITE LIMITEE) (GB) | 2023-09-28 | — | — | US | disclosed |
| CN-115586273-A | Compound non-target identification method based on bromine isotope labeling | 遵义医科大学 | 2023-01-10 | — | — | CN | disclosed |
| US-20220394973-A1 | ANTI-FUNGALS COMPOUNDS TARGETING THE SYNTHESIS OF FUNGAL SPHINGOLIPIDS | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2022-12-15 | — | — | US | disclosed |
| US-20080108625-A1 | Substituted Triazole Derivatives as Oxytocin Antagonists | PFIZER INC | 2008-05-08 | — | — | US | disclosed |
| US-20080108625-A1 | Substituted Triazole Derivatives as Oxytocin Antagonists | PFIZER INC | 2008-05-08 | — | — | US | disclosed |
| US-7291640-B2 | Substituted triazole derivatives as oxytocin antagonists | PFIZER INC. (US) | 2007-11-06 | — | — | US | disclosed |
| US-7291640-B2 | Substituted triazole derivatives as oxytocin antagonists | PFIZER INC. (US) | 2007-11-06 | — | — | US | disclosed |
| US-7291640-B2 | Substituted triazole derivatives as oxytocin antagonists | PFIZER INC. (US) | 2007-11-06 | — | — | US | disclosed |
| EP-1673355-A1 | SUBSTITUTED TRIAZOLE DERIVATIVES AS OXYTOCIN ANTAGONISTS | Pfizer Limited (GB) | 2006-06-28 | — | — | EP | disclosed |
| WO-2005028452-A9 | SUBSTITUTED TRIAZOLE DERIVATIVES AS OXYTOCIN ANTAGONISTS | PFIZER LTD (GB) | 2005-07-21 | — | — | WO | disclosed |
| WO-2005028452-A9 | SUBSTITUTED TRIAZOLE DERIVATIVES AS OXYTOCIN ANTAGONISTS | PFIZER LTD (GB) | 2005-07-21 | — | — | WO | disclosed |
| US-20050107382-A1 | e.g. 2-(4-fluoro-2-methylphenyl)-5-(5-methoxymethyl-4-(6-methoxypyridin-3-yl)-4H-[1,2,4]triazol-3-yl)-pyridine; treatment of arousal disorder, orgasmic disorder, sexual pain disorder and premature ejaculation, preterm labor, appetite and feeding disorders, dysmenorrhoea, congestive heart failure, etc. | PFIZER INC. | 2005-05-19 | — | — | US | disclosed |
| WO-2005028452-A1 | SUBSTITUTED TRIAZOLE DERIVATIVES AS OXYTOCIN ANTAGONISTS | PFIZER LIMITED (GB) | 2005-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220394973-A1 | ANTI-FUNGALS COMPOUNDS TARGETING THE SYNTHESIS OF FUNGAL SPHINGOLIPIDS | ERG28, UGCG, DPM1 | P2RX7 4405/4885KDM4E 1377/4885OGG1 2750/4885 |
| US-12325678-B2 | Anti-fungals compounds targeting the synthesis of fungal sphingolipids | ERG28, UGCG, SMPD1 | P2RX7 4455/4885KDM4E 1113/4885OGG1 2842/4885 |
| US-20230303517-A1 | DIHYDROCYCLOPENTA-ISOQUINOLINE-SULFONAMIDE DERIVATIVES COMPOUNDS | FCER2, FCGR1A, FCGR2A | P2RX7 187/4885KDM4E 1848/4885OGG1 4725/4885 |
| US-20050107382-A1 | e.g. 2-(4-fluoro-2-methylphenyl)-5-(5-methoxymethyl-4-(6-methoxypyridin-3-yl)-4H-[1,2,4]triazol-3-yl)-pyridine; treatment of arousal disorder, orgasmic disorder, sexual pain disorder and premature ejaculation, preterm labor, appetite and feeding disorders, dysmenorrhoea, congestive heart failure, etc. | OXTR, OPRL1, NPY4R | P2RX7 414/4885KDM4E 655/4885OGG1 4829/4885 |
| US-12577228-B2 | Dihydrocyclopenta-isoquinoline-sulfonamide derivatives compounds | FCGR2A, FCER2, FCGR1A | P2RX7 283/4885KDM4E 2965/4885OGG1 2576/4885 |
| US-20080108625-A1 | Substituted Triazole Derivatives as Oxytocin Antagonists | OXTR, PRLHR, KISS1R | P2RX7 611/4885KDM4E 1314/4885OGG1 4291/4885 |
| US-11858880-B2 | Anti-fungals compounds targeting the synthesis of fungal sphingolipids | ERG28, UGCG, DPM1 | P2RX7 4405/4885KDM4E 1377/4885OGG1 2750/4885 |
| US-20240124392-A1 | ANTI-FUNGALS COMPOUNDS TARGETING THE SYNTHESIS OF FUNGAL SPHINGOLIPIDS | ERG28, UGCG, DPM1 | P2RX7 4405/4885KDM4E 1377/4885OGG1 2750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.